Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

DC-402234 enters phase I clinical development in the U.S.

March 16, 2021

New diphtheria threat as antimicrobial resistance evolves

March 16, 2021

DARPins as promising mutation-resistant antivirals for potential SARS-CoV-2 treatment

March 15, 2021

I-SPY COVID trial drops apremilast for futility

March 15, 2021

ALG-097111: targeting 3CLpro for treating SARS-CoV-2

March 15, 2021

Successful completion of IND-enabling rodent toxicology studies with R-107

March 15, 2021

Immune response research shows GM-CSF plays role in COVID-19 severity

March 15, 2021

European Commission grants conditional marketing authorization for J&J COVID-19 vaccine

March 12, 2021

Brilacidin inhibits SARS-CoV-2 in vitro

March 12, 2021

SymBio submits IND for phase II trial of intravenous brincidofovir for pediatric AdV infections

March 12, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...